Teva price target raised to $45 from $42 at Truist

Truist raised the firm’s price target on Teva (TEVA) to $45 from $42 and keeps a Buy rating on the shares after announcing “strong” Q1 results, and the acquisition of Emalex Biosciences. The firm noted the latest acquisition of new drug application-ready Tourette Syndrome asset paves the path for a potential $1B peak sales opportunity with at least seven-year exclusivity. Truist added that Q1 results tack on to the latest trends and prove Teva’s management team continues to outperform.